Breast cancer is one of the most common cancers. Although the present molecular classification improves the treatment effect and prognosis of breast cancer, the heterogeneity of the molecular subtype
Clinical heterogeneity of esrtrogen receptor-negative, progesterone receptor-negative [ER(-)/PR(-)] breast cancer (BC) suggests biological heterogeneity. We performed gene expression analysis of prima
Flow cytometry were used to explore univariate associations of baseline peripheral blood immune profile with week 12 overall response. Conclusion: Pembrolizumab with paclitaxel or capecitabine is saf
